IRADIMED CORP Form 8-K Summary
Business Context and Reporting Period
IRADIMED CORPORATION (IRMD), a Delaware corporation, filed this Current Report on Form 8-K on August 1, 2024. The filing serves to announce the company's financial results for the quarter ended June 30, 2024, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the press release (Exhibit 99.1) but are not detailed in the body of this 8-K document.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative financial analysis.
Guidance, Outlook, and Risks
This 8-K filing does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the specific revenue and net income figures for the quarter ended June 30, 2024, by reviewing the press release attached as Exhibit 99.1.
- Confirm whether the company provided updated full-year guidance in the referenced press release.
- Note that the financial data in this 8-K is not legally "filed" under Section 18 of the Exchange Act, limiting liability exposure for the company regarding these specific figures.
- Check the NASDAQ Capital Market listing status for the common stock trading symbol IRMD.